Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma

Inclusion Criteria: * Patients having relapsed/refractory multiple myeloma and neuropathy (or who are otherwise unable to tolerate bortezomib) * Aged 18 years and older * Patient able to provide written, informed consent to participate in and follow the KEAP Treatment Plan Exclusion Criteria: * Known hypersensitivity to selinexor or any excipients. * Patient receiving any other investigational agent. * Any concurrent uncontrolled and active medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.). * Known intolerance, hypersensitivity, or contraindication to glucocorticoids. * Active graft versus host disease (after allogeneic stem cell transplantation). * Active, unstable cardiovascular function: * Symptomatic ischemia, or uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics) * Congestive heart failure of New York Heart Association Class ≥ 3 or known leftventricular ejection fraction \< 40%, or * Myocardial infarction within 3 months prior to C1D1. * Significant renal impairment with ongoing dialysis treatment * Active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could, in the treating physician's opinion, interfere with absorption of treatment. * Any active, serious psychiatric, medical, or other conditions/situations which, in the treating physician's opinion, could compromise the patient's safety.